Diagnostic Strategies for Breast Cancer Detection: From Image Generation to Classification Strategies Using Artificial Intelligence Algorithms

Detection and Classification of Histopathological Breast Images Using a Fusion of CNN Frameworks

Breast cancer is responsible for the deaths of thousands of women each year. The diagnosis of breast cancer (BC) frequently makes the use of several imaging techniques. On the other hand, incorrect identification might occasionally result in unnecessary therapy and diagnosis. Therefore, the accurate identification of breast cancer can save a significant number of patients from undergoing unnecessary surgery and biopsy procedures. As a result of recent developments in the field, the performance of deep learning systems used for medical image processing has showed significant benefits. Deep learning (DL) models have found widespread use for the aim of extracting important features from histopathologic BC images. This has helped to improve the classification performance and has assisted in the automation of the process. In recent times, both convolutional neural networks (CNNs) and hybrid models of deep learning-based approaches have demonstrated impressive performance. In this research, three different types of CNN models are proposed: a straightforward CNN model (1-CNN), a fusion CNN model (2-CNN), and a three CNN model (3-CNN). The findings of the experiment demonstrate that the techniques based on the 3-CNN algorithm performed the best in terms of accuracy (90.10%), recall (89.90%), precision (89.80%), and f1-Score (89.90%). In conclusion, the CNN-based approaches that have been developed are contrasted with more modern machine learning and deep learning models. The application of CNN-based methods has resulted in a significant increase in the accuracy of the BC classification.

Future of Artificial Intelligence Applications in Cancer Care: A Global Cross-Sectional Survey of Researchers

Cancer significantly contributes to global mortality, with 9.3 million annual deaths. To alleviate this burden, the utilization of artificial intelligence (AI) applications has been proposed in various domains of oncology. However, the potential applications of AI and the barriers to its widespread adoption remain unclear. This study aimed to address this gap by conducting a cross-sectional, global, web-based survey of over 1000 AI and cancer researchers. The results indicated that most respondents believed AI would positively impact cancer grading and classification, follow-up services, and diagnostic accuracy. Despite these benefits, several limitations were identified, including difficulties incorporating AI into clinical practice and the lack of standardization in cancer health data. These limitations pose significant challenges, particularly regarding testing, validation, certification, and auditing AI algorithms and systems. The results of this study provide valuable insights for informed decision-making for stakeholders involved in AI and cancer research and development, including individual researchers and research funding agencies.

Biomedical Diagnosis of Breast Cancer Using Deep Learning and Multiple Classifiers

Breast cancer is considered one of the deadliest diseases in women. Due to the risk and threat it poses, the world has agreed to hold a breast cancer awareness day in October, encouraging women to perform mammogram inspections. This inspection may prevent breast-cancer-related deaths or reduce the death rate. The identification and classification of breast cancer are challenging tasks. The most commonly known procedure of breast cancer detection is performed by using mammographic images. Recently implemented algorithms suffer from generating accuracy below expectations, and their computational complexity is high. To resolve these issues, this paper proposes a fully automated biomedical diagnosis system of breast cancer using an AlexNet, a type of Convolutional Neural Network (CNN), and multiple classifiers to identify and classify breast cancer. This system utilizes a neuro-fuzzy method, a segmentation algorithm, and various classifiers to reach a higher accuracy than other systems have achieved. Numerous features are extracted to detect and categorize breast cancer. Three datasets from Kaggle were tested to validate the proposed system. The performance evaluation is performed with quantitative and qualitative accuracy, precision, recall, specificity, and F-score. In addition, a comparative assessment is performed between the proposed system and some works of literature. This assessment shows that the presented algorithm provides better classification results and outperforms other systems in all parameters. Its average accuracy is over 98.6%, while other metrics are more than 98%. This research indicates that this approach can be applied to assist doctors in diagnosing breast cancer correctly.

Artificial Intelligence Predicted Overall Survival and Classified Mature B-Cell Neoplasms Based on Immuno-Oncology and Immune Checkpoint Panels

Artificial intelligence (AI) can identify actionable oncology biomarkers. This research integrates our previous analyses of non-Hodgkin lymphoma. We used gene expression and immunohistochemical data, focusing on the immune checkpoint, and added a new analysis of macrophages, including 3D rendering. The AI comprised machine learning (C5, Bayesian network, C&R, CHAID, discriminant analysis, KNN, logistic regression, LSVM, Quest, random forest, random trees, SVM, tree-AS, and XGBoost linear and tree) and artificial neural networks (multilayer perceptron and radial basis function). The series included chronic lymphocytic leukemia, mantle cell lymphoma, follicular lymphoma, Burkitt, diffuse large B-cell lymphoma, marginal zone lymphoma, and multiple myeloma, as well as acute myeloid leukemia and pan-cancer series. AI classified lymphoma subtypes and predicted overall survival accurately. Oncogenes and tumor suppressor genes were highlighted (MYC, BCL2, and TP53), along with immune microenvironment markers of tumor-associated macrophages (M2-like TAMs), T-cells and regulatory T lymphocytes (Tregs) (CD68, CD163, MARCO, CSF1R, CSF1, PD-L1/CD274, SIRPA, CD85A/LILRB3, CD47, IL10, TNFRSF14/HVEM, TNFAIP8, IKAROS, STAT3, NFKB, MAPK, PD-1/PDCD1, BTLA, and FOXP3), apoptosis (BCL2, CASP3, CASP8, PARP, and pathway-related MDM2, E2F1, CDK6, MYB, and LMO2), and metabolism (ENO3, GGA3). In conclusion, AI with immuno-oncology markers is a powerful predictive tool. Additionally, a review of recent literature was made.